Welcome to our dedicated page for Humana SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humana Inc. filings document formal disclosures for a public healthcare company with Humana insurance services and CenterWell healthcare services. Recent 8-K reports cover quarterly results, GAAP and non-GAAP earnings measures, Insurance segment benefit ratio commentary, Medicare Advantage membership assumptions, Regulation FD communications, and guidance updates.
Humana's SEC records also include proxy and annual-meeting materials covering director elections, auditor ratification, stockholder voting results, board composition, and director compensation program disclosures; board and executive transition disclosures; and capital-structure filings for registered debt offerings, including junior subordinated notes described through Form S-3 and prospectus-supplement materials.
Humana Inc. director Gordon Smith reported changes in his equity holdings. A Form 4 filing shows he disposed of 765 shares of Humana common stock and received additional equity-based awards tied to his director compensation.
The filing reports 766 restricted stock units from his annual director fee, which are deferred and will convert into Humana common stock on a 1-for-1 basis when he leaves the board. It also shows 122 stock units from electing to convert his cash director fees into stock units and 10 additional stock units from the reinvestment of dividends on previously vested and deferred units. All of these awards are structured as deferred stock units payable in Humana common stock, consistent with the company’s director compensation and deferral plan.
Humana Inc. director Raquel C. Bono reported equity awards and deferrals. The filing shows she acquired 766 restricted stock units as part of her annual director fee, which she elected to receive in stock units rather than cash. These units are deferred until she resigns from the board, at which time they will be settled in Humana common shares on a one-for-one basis under the company’s 2019 Amended & Restated Plan.
She also reported 34 additional stock units from dividend payments that were reinvested on already vested and deferred stock units. These dividend units are likewise deferred until she leaves board service and will then be paid in Humana common stock on a one-for-one basis.
Humana Inc. reported an insider equity transaction by its Chief Human Resources Officer, Michelle A. O'Hara. On 01/01/2026, she acquired 2,353 shares of Humana common stock through a transaction coded "M," at an exercise price of $0, reflecting the vesting or exercise of previously granted equity awards.
On the same date, she disposed of 1,093 shares, coded "F," at a price of $258.8675 per share, to cover tax liabilities related to shares vesting on that date, with no value received in return. After these transactions, she beneficially owned 9,541 shares of Humana common stock, which includes 7,512 restricted stock units that each represent a contingent right to receive one share under the company's 2019 Amended & Restated Plan.
Humana Inc. reported insider share transactions by its Chief Financial Officer, Celeste Mellet, dated 12/15/2025. She acquired 2,128 shares of Humana common stock at a price of $0, and 1,222 shares were disposed of at $270.155 per share to pay tax liabilities on vesting shares, with no value received in return.
Following these transactions, Mellet beneficially owned 28,454 Humana shares directly. This total includes 27,548 restricted stock units, each representing a contingent right to receive one share of Humana common stock under the Company's 2019 Amended & Restated Plan.
Humana Inc. reported insider share transactions by its Chief Financial Officer, Celeste Mellet, dated 12/15/2025. She acquired 2,128 shares of Humana common stock at a price of $0, and 1,222 shares were disposed of at $270.155 per share to pay tax liabilities on vesting shares, with no value received in return.
Following these transactions, Mellet beneficially owned 28,454 Humana shares directly. This total includes 27,548 restricted stock units, each representing a contingent right to receive one share of Humana common stock under the Company's 2019 Amended & Restated Plan.
Humana Inc. Chief Information Officer Japan Mehta reported equity compensation activity in Humana common stock. On 12/15/2025, 1,194 shares were acquired at a reported price of $0, and 470 shares were disposed of at $270.155 to satisfy tax liability related to shares vesting on that date, with no value received in return.
After these transactions, Mehta beneficially owned 8,158 Humana shares directly. This total includes 7,434 restricted stock units that represent a contingent right to receive one share of Humana common stock each under the company’s 2019 Amended & Restated Plan. The report was signed on 12/17/2025.
Humana Inc. Chief Information Officer Japan Mehta reported equity compensation activity in Humana common stock. On 12/15/2025, 1,194 shares were acquired at a reported price of $0, and 470 shares were disposed of at $270.155 to satisfy tax liability related to shares vesting on that date, with no value received in return.
After these transactions, Mehta beneficially owned 8,158 Humana shares directly. This total includes 7,434 restricted stock units that represent a contingent right to receive one share of Humana common stock each under the company’s 2019 Amended & Restated Plan. The report was signed on 12/17/2025.
Humana Inc. disclosed an insider stock transaction by its President, Enterprise Growth, David Dintenfass. On 12/15/2025 he exercised stock options for 2,032 shares of Humana common stock at an exercise price of $0 under the company’s 2019 Amended & Restated Stock Incentive Plan.
On the same date, 918 shares were disposed of at $270.155 per share to cover tax liabilities on vested restricted stock units, leaving 15,316 shares of common stock held directly, including 11,202 restricted stock units that each represent a right to receive one share. He also continues to hold stock options covering 51,389 shares at an exercise price of $367.21 per share, expiring on 02/21/2031 and vesting in three annual installments from 02/21/2025 through 02/21/2027.
Humana Inc. disclosed an insider stock transaction by its President, Enterprise Growth, David Dintenfass. On 12/15/2025 he exercised stock options for 2,032 shares of Humana common stock at an exercise price of $0 under the company’s 2019 Amended & Restated Stock Incentive Plan.
On the same date, 918 shares were disposed of at $270.155 per share to cover tax liabilities on vested restricted stock units, leaving 15,316 shares of common stock held directly, including 11,202 restricted stock units that each represent a right to receive one share. He also continues to hold stock options covering 51,389 shares at an exercise price of $367.21 per share, expiring on 02/21/2031 and vesting in three annual installments from 02/21/2025 through 02/21/2027.
Humana Inc. executive Sanjay K. Shetty, President of CenterWell, reported multiple equity award transactions dated 12/15/2025. He acquired 1,968 and 308 Humana common shares through equity awards at $0 per share, and disposed of 888 and 139 shares at $270.155 per share to satisfy tax liabilities on vesting, with no additional value received.
After these transactions, he directly beneficially owns 10,847 Humana common shares, which includes 8,818 restricted stock units that each represent a contingent right to one share. He also holds stock options covering 3,964 shares at an exercise price of $487.1602 expiring 04/01/2030 and 6,572 shares at $367.21 expiring 02/21/2031, all granted under Humana’s 2019 Amended & Restated Stock Incentive Plan.
Humana Inc. executive Sanjay K. Shetty, President of CenterWell, reported multiple equity award transactions dated 12/15/2025. He acquired 1,968 and 308 Humana common shares through equity awards at $0 per share, and disposed of 888 and 139 shares at $270.155 per share to satisfy tax liabilities on vesting, with no additional value received.
After these transactions, he directly beneficially owns 10,847 Humana common shares, which includes 8,818 restricted stock units that each represent a contingent right to one share. He also holds stock options covering 3,964 shares at an exercise price of $487.1602 expiring 04/01/2030 and 6,572 shares at $367.21 expiring 02/21/2031, all granted under Humana’s 2019 Amended & Restated Stock Incentive Plan.
Humana Inc. executive Michelle A. O'Hara reported routine equity compensation activity. On 12/15/2025, she acquired 1,401 shares of Humana common stock at $0 per share through a transaction coded "M". On the same date, 632 shares coded "F" were disposed of at $270.155 per share to cover tax liabilities on shares vesting that day, with no value received in return. After these transactions, she beneficially owned 10,634 shares, including 9,865 restricted stock units that each represent a contingent right to receive one share of Humana common stock under the company's 2019 Amended & Restated Plan.
Humana Inc. executive Michelle A. O'Hara reported routine equity compensation activity. On 12/15/2025, she acquired 1,401 shares of Humana common stock at $0 per share through a transaction coded "M". On the same date, 632 shares coded "F" were disposed of at $270.155 per share to cover tax liabilities on shares vesting that day, with no value received in return. After these transactions, she beneficially owned 10,634 shares, including 9,865 restricted stock units that each represent a contingent right to receive one share of Humana common stock under the company's 2019 Amended & Restated Plan.
Humana Inc.'s president and CEO James A. Rechtin reported equity transactions in company stock dated 12/15/2025.
He acquired 7,707 shares of Humana common stock at $0 per share through an option exercise, then disposed of 3,372 shares at $270.155 per share to satisfy tax liabilities for shares vesting on that date. After these transactions, he indirectly beneficially owned 27,102 shares, including 14,054 restricted stock units, held in revocable trusts for himself and his spouse.
He also holds stock options exercisable for 29,230 shares at $458.185 per share until 01/08/2031 and options for 15,772 shares at $367.21 per share until 02/21/2031, plus 4,366 additional restricted stock units.
Humana Inc.'s president and CEO James A. Rechtin reported equity transactions in company stock dated 12/15/2025.
He acquired 7,707 shares of Humana common stock at $0 per share through an option exercise, then disposed of 3,372 shares at $270.155 per share to satisfy tax liabilities for shares vesting on that date. After these transactions, he indirectly beneficially owned 27,102 shares, including 14,054 restricted stock units, held in revocable trusts for himself and his spouse.
He also holds stock options exercisable for 29,230 shares at $458.185 per share until 01/08/2031 and options for 15,772 shares at $367.21 per share until 02/21/2031, plus 4,366 additional restricted stock units.
Humana Inc. Chief Legal Officer Joseph C. Ventura reported several insider transactions in Humana common stock dated 12/15/2025. He acquired 2,046 shares and an additional 360 shares at an exercise price of $0 per share through stock option and restricted stock unit activity. To cover tax obligations on vesting shares, he disposed of 933 and 164 shares at $270.155 per share, with no value received in return.
After these transactions, Ventura beneficially owns 16,530 Humana common shares directly, including 6,250 restricted stock units, and 290 shares held indirectly in the Humana Retirement Savings Plan. He also holds stock options granted under Humana’s 2019 Amended & Restated Stock Incentive Plan covering 4,656, 4,598, 3,932, 4,162 and 6,572 shares, with exercise prices from $350.7875 to $510.2425 and expirations between 02/24/2027 and 02/21/2031.
Humana Inc. Chief Legal Officer Joseph C. Ventura reported several insider transactions in Humana common stock dated 12/15/2025. He acquired 2,046 shares and an additional 360 shares at an exercise price of $0 per share through stock option and restricted stock unit activity. To cover tax obligations on vesting shares, he disposed of 933 and 164 shares at $270.155 per share, with no value received in return.
After these transactions, Ventura beneficially owns 16,530 Humana common shares directly, including 6,250 restricted stock units, and 290 shares held indirectly in the Humana Retirement Savings Plan. He also holds stock options granted under Humana’s 2019 Amended & Restated Stock Incentive Plan covering 4,656, 4,598, 3,932, 4,162 and 6,572 shares, with exercise prices from $350.7875 to $510.2425 and expirations between 02/24/2027 and 02/21/2031.